ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer. - Wikidata - awgldk - TriplyDB

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.

http://www.wikidata.org/entity/Q33769990

about

Problems of variable biomarker evaluation in stratified medicine research--A case study of ERCC1 in non-small-cell lung cancer The role of epigenetics in resistance to Cisplatin chemotherapy in lung cancer Proteomics and biomarkers in clinical trials for drug development Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS).Real-time monitoring efficiency and toxicity of chemotherapy in patients with advanced lung cancer.ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy.ERCC1 Expression in Non-Small Cell Lung and Esophageal Cancer.Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.Osteopontin promotes cancer cell drug resistance, invasion, and lactate production and is associated with poor outcome of patients with advanced non-small-cell lung cancer

P2860

Q28069810-5D298951-026E-4ADD-9DA4-C67F7F4A3B31 Q28387891-B9D72309-48B8-40AD-91ED-7E2A83C60EDA Q30402667-4CDB3214-8A4F-4023-9780-74C302043B74 Q34367452-9E2768F9-0014-4C54-A685-76F939584BED Q36256718-275EE72E-0D35-4B67-B29A-57D8F544CEC2 Q41721741-C29FD09B-C041-41D5-9BB2-C655F7E436A2 Q41961362-056E32F0-BE36-4081-9666-A80B9848FEE4 Q47309064-500F5C57-E5B8-4575-89FB-DC6333BC4658 Q57073431-1EA7E797-F156-4A1E-9A35-58847ECD363F

P2860

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.

http://www.wikidata.org/entity/Q33769990

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.

@ast

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.

@en

type

label

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.

@ast

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.

@en

prefLabel

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.

@ast

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.

@en

P1433

Q33769990-7F39F489-5F25-4AAF-9CC6-8CF741CE3021

P1476

Q33769990-440BE134-0A88-422E-BF79-095F36B34FF7

P2093

Q33769990-228E4EB1-59DC-4B60-9B53-A3EF8A4C9DC7

Q33769990-846F6BFB-FEE7-4D60-A875-CDD308923056

Q33769990-E32A974F-D319-4B78-B1F9-4A9B2D1BF327

P2860

Q33769990-1A79DFEA-2807-49AF-9640-8EAA6426F39B

Q33769990-1FC9202E-B91A-4ECD-BDDC-E5A22B93D7B1

Q33769990-27FCACF6-47ED-443C-9B66-8739CFC1EAB5

Q33769990-316518D6-0E9C-4379-B187-2F44BB66C173

Q33769990-3386930F-6295-4C6E-AB99-0C1DA63C210C

Q33769990-348F15A5-061C-4742-9B8C-8D7F99A80AB3

Q33769990-34C2DC91-D074-4EE6-9908-FB7949165A2C

Q33769990-45165CD7-DA07-4415-A71A-C3AA6DD7F20D

Q33769990-486CCD94-47F8-4F50-BCE1-9B5BFDC1C1FC

Q33769990-5AB8D64C-C26A-473D-84E4-9DB943D81234

P304

Q33769990-CA40C017-1C56-4551-A2AB-5CC4D5258555

P31

Q33769990-471804C3-74E8-48EE-BEA7-978349C2D7A6

P356

Q33769990-5835CAD8-258B-42D0-9BA1-E632B1067B44

P478

Q33769990-6B72B8E9-6CF1-4D0C-8B3A-6D5D0B089DD9

P577

Q33769990-F6732B53-86FF-43A9-94D7-40A82E89B9E0

P698

Q33769990-CAD0C067-E7F5-4E7F-AB68-B74453F4E79F

P932

Q33769990-B89BE66A-8B17-4C37-AD36-2FF6DE6C7E66

P356

CURRENTS.RRN1202

P1433

P1476

ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer.

@en

P2093

Andrew Lea

http://www.w3.org/2001/XMLSchema#string

Diane Allingham-Hawkins

http://www.w3.org/2001/XMLSchema#string

Susan Levine

http://www.w3.org/2001/XMLSchema#string

P2860

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.

Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.

From the bench to the bed: individualizing treatment in non-small-cell lung cancer.

Pharmacogenomics and gemcitabine.

Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality.

The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer.

Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.

Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.

P304

RRN1202

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/CURRENTS.RRN1202

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2010-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21152077

http://www.w3.org/2001/XMLSchema#string

P932

2998231

http://www.w3.org/2001/XMLSchema#string